Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer
Boennuokang<sup>®</sup> leuprorelin acetate microspheres-based treatment as neoadjuvant therapy decreases PSA, testosterone, and prostate volume, with acceptable positive surgical margin rate in patients with high-risk prostate cancer and its safety profiles should be validated.
Authors
- Yongnan Wang
- Wei Zhang (ORCID: https://orcid.org/0000-0002-0279-951X)
- Xu Zeng (ORCID: https://orcid.org/0009-0008-3768-9776)
- Jinjin Lai (ORCID: https://orcid.org/0000-0002-3109-5079)
- Jun Xin
- Changde Fu
Institutions
- Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3389/fonc.2025.1520370
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52